Effects of resveratrol and genistein on nuclear factor‑κB, tumor necrosis factor‑α and matrix metalloproteinase‑9 in patients with chronic obstructive pulmonary disease

Liu,Xiao‑Ju; Bao,Hai‑Rong; Zeng,Xiao‑Li; Wei,Jun‑Ming

doi:10.3892/mmr.2016.5057

Effects of resveratrol and genistein on nuclear factor‑κB, tumor necrosis factor‑α and matrix metalloproteinase‑9 in patients with chronic obstructive pulmonary disease

Authors:
- Xiao‑Ju Liu
- Hai‑Rong Bao
- Xiao‑Li Zeng
- Jun‑Ming Wei
View Affiliations

Affiliations: Department of Gerontal Respiratory Medicine, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China
Published online on: March 28, 2016 https://doi.org/10.3892/mmr.2016.5057
Pages: 4266-4272
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic airway inflammation and airway remodeling are the major pathophysiological characteristics of chronic obstructive pulmonary disease (COPD). Resveratrol and genistein have been previously demonstrated to have anti‑inflammatory and antioxidative properties. The present study aimed to measure the inhibitory effects of resveratrol and genistein on tumor necrosis factor (TNF)‑α and matrix metalloproteinase (MMP)‑9 concentration in patients with COPD. Lymphocytes were isolated from the blood of 34 patients with COPD and 30 healthy subjects, then randomly divided into the following four treatment groups: Control, dexamethasone (0.5 µmol/l), resveratrol (12.5 µmol/l) and genistein (25 µmol/l) groups. After 1 h of treatment, 100 µl lymphocytes were collected for nuclear factor (NF)‑κB immunocytochemical staining. After 48 h treatment, the supernatant of the lymphocytes was collected for analysis of TNF‑α and MMP‑9 concentration levels. The percentage of lymphocytes with positive nuclear NF‑κB expression was analyzed by immunocytochemical staining. The concentration levels of TNF‑α and MMP‑9 were measured using radioimmunoassay and enzyme‑linked immunosorbent assay, respectively. The present study demonstrated that the percentage of NF‑κB‑positive cells, and the levels of TNF‑α and MMP‑9 in lymphocytes from patients with COPD patients were significantly higher compared with healthy subjects. Additionally, there were positive correlations between the percentage of NF‑κB‑positive cells, and the concentration levels of TNF‑α and MMP‑9 in patients with COPD. All three factors were significantly reduced in lymphocytes treated with resveratrol and genistein, and the inhibitory effects of resveratrol on NF‑κB, TNF‑α and MMP‑9 were more potent than the effects of genistein. In conclusion, resveratrol and genistein may inhibit the NF‑κB, TNF‑α and MMP‑9‑associated pathways in patients with COPD. It is suggested that resveratrol and genistein may be potential drugs candidates for use in the treatment of COPD.

View Figures

View References

1	Barnes PJ: Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 35:71–86. 2014. View Article : Google Scholar : PubMed/NCBI
2	Eurlings IM, Dentener MA, Mercken EM, de Cabo R, Bracke KR, Vernooy JH, Wouters EF and Reynaert NL: A comparative study of matrix remodeling in chronic models for COPD; mechanistic insights into the role of TNF-α. Am J Physiol Lung Cell Mol Physiol. 307:L557–L565. 2014. View Article : Google Scholar : PubMed/NCBI
3	Mohan D, Gale NS, McEniery CM, Bolton CE, Cockcroft JR, MacNee W, Fuld J, Lomas DA, Calverley PM, Shale DJ, et al ERICA Consortium: Evaluating the role of inflammation in chronic airways disease: The ERICA study. COPD. 11:552–559. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kersul AL, Iglesias A, Ríos Á, Noguera A, Forteza A, Serra E, Agustí A and Cosío BG: Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 47:176–183. 2011. View Article : Google Scholar : PubMed/NCBI
5	Barnes PJ and Karin M: Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 336:1066–1071. 1997. View Article : Google Scholar : PubMed/NCBI
6	Jayasooriya RG, Dilshara MG, Park SR, Choi YH, Hyun JW, Chang WY and Kim GY: 18β-Glycyrrhetinic acid suppresses TNF-α induced matrix metalloproteinase-9 and vascular endothelial growth factor by suppressing the Akt-dependent NF-κB pathway. Toxicol In Vitro. 28:751–758. 2014. View Article : Google Scholar : PubMed/NCBI
7	Tung BT, Rodríguez-Bies E, Talero E, Gamero-Estévez E, Motilva V, Navas P and López-Lluch G: Anti-inflammatory effect of resveratrol in old mice liver. Exp Gerontol. 64:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
8	Park EJ and Pezzuto JM: The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. 1852.1071–1113. 2015.
9	Chen L, Yang S, Zumbrun EE, Guan H, Nagarkatti PS and Nagarkatti M: Resveratrol attenuates lipopolysaccharide-induced acute kidney injury by suppressing inflammation driven by macrophages. Mol Nutr Food Res. 59:853–864. 2015. View Article : Google Scholar : PubMed/NCBI
10	Chen J, Zhou H, Wang J, Zhang B, Liu F, Huang J, Li J, Lin J, Bai J and Liu R: Therapeutic effects of resveratrol in a mouse model of HDM-induced allergic asthma. Int Immunopharmacol. 25:43–48. 2015. View Article : Google Scholar : PubMed/NCBI
11	Shao AW, Wu HJ, Chen S, Ammar AB, Zhang JM and Hong Y: Resveratrol attenuates early brain injury after subarachnoid hemorrhage through inhibition of NF-κB-dependent inflammatory/MMP-9 pathway. CNS Neurosci Ther. 20:182–185. 2014. View Article : Google Scholar
12	Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S and Aggarwal BB: Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 559:91–99. 2014. View Article : Google Scholar : PubMed/NCBI
13	Gao F, Wei D, Bian T, Xie P, Zou J, Mu H, Li J, Lin J, Bai J and Liu R: Genistein attenuated allergic airway inflammation by modulating the transcription factors T-bet, GATA-3 and STAT-6 in a murine model of asthma. Pharmacology. 89:229–236. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Dong J, He P, Li W, Zhang Q, Li N and Sun T: Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis. Inflammation. 35:377–387. 2012. View Article : Google Scholar
15	Liu XJ, Zhao J and Gu XY: The effects of genistein and puerarin on the activation of nuclear factor-kappaB and the production of tumor necrosis factor-alpha in asthma patients. Pharmazie. 65:127–131. 2010.PubMed/NCBI
16	Global Initiative for Chronic Obstructive Lung Disease(GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. http://www.goldcopd.org. Accessed December 31, 2011.
17	Martin-Piedra MA, Garzon I, Oliveira AC, Alfonso-Rodriguez CA, Carriel V, Scionti G and Alaminos M: Cell viability and proliferation capability of long-term human dental pulp stem cell cultures. Cytotherapy. 16:266–277. 2014. View Article : Google Scholar : PubMed/NCBI
18	Singh R, Mackay AJ, Patel AR, Garcha DS, Kowlessar BS, Brill SE, Donnelly LE, Barnes PJ, Donaldson GC and Wedzicha JA: Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res. 15:1142014. View Article : Google Scholar : PubMed/NCBI
19	Fischer BM, Voynow JA and Ghio AJ: COPD: Balancing oxidants and antioxidants. Int J Chron Obstruct Pulmon Dis. 10:261–276. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hirota N and Martin JG: Mechanisms of airway remodeling. Chest. 144:1026–1032. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yao H, Hwang JW, Sundar IK, Friedman AE, McBurney MW, Guarente L, Gu W, Kinnula VL and Rahman I: SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol. 305:L615–L624. 2013. View Article : Google Scholar : PubMed/NCBI
22	Gross NJ: Novel antiinflammatory therapies for COPD. Chest. 142:1300–1307. 2012. View Article : Google Scholar : PubMed/NCBI
23	Knobloch J, Wahl C, Feldmann M, Jungck D, Strauch J, Stoelben E and Koch A: Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic acid in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol. 114:202–209. 2014. View Article : Google Scholar
24	Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ and Belvisi MG: Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J. 19:840–841. 2005.PubMed/NCBI
25	Lee SJ and Kim M: Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sci. 88:465–472. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yu H, Pan C, Zhao S, Wang Z, Zhang H and Wu W: Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 62:366–372. 2008. View Article : Google Scholar
27	Knobloch J, Hag H, Jungck D, Urban K and Koch A: Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol. 109:138–143. 2011. View Article : Google Scholar : PubMed/NCBI
28	Bime C, Wei CY, Holbrook J, Smith LJ and Wise RA: Association of dietary soy genistein intake with lung function and asthma control: A post-hoc analysis of patients enrolled in a prospective multicentre clinical trial. Prim Care Respir J. 21:398–404. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kalhan R, Smith LJ, Nlend MC, Nair A, Hixon JL and Sporn PH: A mechanism of benefit of soy genistein in asthma: Inhibition of eosinophil p38-dependent leukotriene synthesis. Clin Exp Allergy. 38:103–112. 2008.
30	Hirayama F, Lee AH, Binns CW, Hiramatsu N, Mori M and Nishimura K: Dietary intake of isoflavones and polyunsaturated fatty acids associated with lung function, breathlessness and the prevalence of chronic obstructive pulmonary disease: Possible protective effect of traditional Japanese diet. Mol Nutr Food Res. 54:909–917. 2010. View Article : Google Scholar : PubMed/NCBI
31	Li J, Li J, Yue Y, Hu Y, Cheng W, Liu R, Pan X and Zhang P: Genistein suppresses tumor necrosis factor α-induced inflammation via modulating reactive oxygen species/Akt/nuclear factor κB and adenosine monophosphate-activated protein kinase signal pathways in human synoviocyte MH7A cells. Drug Des Devel Ther. 8:315–323. 2014. View Article : Google Scholar
32	Jeong JW, Lee HH, Han MH, Kim GY, Kim WJ and Choi YH: Anti-inflammatory effects of genistein via suppression of the toll-like receptor 4-mediated signaling pathway in lipopolysaccharide-stimulated BV2 microglia. Chem Biol Interact. 212:30–39. 2014. View Article : Google Scholar : PubMed/NCBI
33	Wu CY, Hsieh HL, Sun CC, Tseng CP and Yang CM: IL-1 beta induces proMMP-9 expression via c-Src-dependent PDGFR/PI3K/Akt/p300 cascade in rat brain astrocytes. J Neurochem. 105:1499–1512. 2008. View Article : Google Scholar : PubMed/NCBI